Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -15.72% is in line with its 5-year average of -14.56%, near the low end of its 5-year range (-38.86%–53.04%).
4.21% below its 12-month average of -15.09%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -10.16%.
NET PROFIT MARGIN
-15.72%
NET PROFIT MARGIN AVG TTM
-15.09%
NET PROFIT MARGIN AVG 3Y
-14.64%
NET PROFIT MARGIN AVG 5Y
-14.56%
NET PROFIT MARGIN AVG 10Y
-17.79%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.21%
CURRENT VS 3Y AVG
-7.35%
CURRENT VS 5Y AVG
-7.96%
CURRENT VS 10Y AVG
+11.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-4391.43%
vs the sector median at left
OrthoPediatrics Corp.
Market Cap
$583.31M
Net Profit Margin
-15.72%
TTM Avg
-15.09%
3Y Avg
-14.64%
5Y Avg
-14.56%
Market Cap
$584.48M
Net Profit Margin
-26.05%
TTM Avg
-16.91%
3Y Avg
-17.17%
5Y Avg
5.54%
Market Cap
$578.40M
Net Profit Margin
-144.63%
TTM Avg
-132.38%
3Y Avg
-98.61%
5Y Avg
-109.15%
Market Cap
$571.13M
Net Profit Margin
40.49%
TTM Avg
5.54%
3Y Avg
-11349.71%
5Y Avg
-11563.54%
Market Cap
$596.01M
Net Profit Margin
-11.48%
TTM Avg
-11.55%
3Y Avg
-24.81%
5Y Avg
-19.75%
Market Cap
$597.55M
Net Profit Margin
33.36%
TTM Avg
4.18%
3Y Avg
-43.84%
5Y Avg
-3.40%
Market Cap
$557.32M
Net Profit Margin
-435.21%
TTM Avg
0.14%
3Y Avg
-46.77%
5Y Avg
-98.73%
Market Cap
$611.57M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OrthoPediatrics Corp. (KIDS) | $583.31M | -15.72% | -15.09% | -14.64% | -14.56% |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | -26.05% | -16.91% | -17.17% | 5.54% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.40M | -144.63% | -132.38% | -98.61% | -109.15% |
| CorMedix Inc. (CRMD)vs › | $571.13M | 40.49% | 5.54% | -11349.71% | -11563.54% |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | -11.48% | -11.55% | -24.81% | -19.75% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 33.36% | 4.18% | -43.84% | -3.40% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | -435.21% | 0.14% | -46.77% | -98.73% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | 0.00% | 0.00% | 0.00% | 0.00% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | -41.34% | -365.72% | -7572.59% | -5048.40% |
Operating Margin
-9.0%
Net Profit Margin
-15.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -10.16% |
| 2026-03-31 | -18.00% |
| 2025-12-31 | -16.40% |
| 2025-09-30 | -19.22% |
| 2025-06-30 | -11.65% |
| 2025-03-31 | -20.34% |
| 2024-12-31 | -30.51% |
| 2024-09-30 | -14.51% |
| 2024-06-30 | -11.42% |
| 2024-03-31 | -17.47% |
| 2023-12-31 | -17.79% |
| 2023-09-30 | -11.49% |
| 2023-06-30 | -7.30% |
| 2023-03-31 | -21.55% |
| 2022-12-31 | -25.32% |
| 2022-09-30 | 53.04% |
| 2022-06-30 | -1.01% |
| 2022-03-31 | -38.86% |
| 2021-12-31 | 0.29% |
| 2021-09-30 | -8.76% |
| 2021-06-30 | -14.07% |
| 2021-03-31 | -48.36% |
| 2020-12-31 | -74.05% |
| 2020-09-30 | -20.44% |
| 2020-06-30 | -69.50% |
| 2020-03-31 | -30.23% |
| 2019-12-31 | -28.65% |
| 2019-09-30 | -12.84% |
| 2019-06-30 | -14.38% |
| 2019-03-31 | -20.61% |
| 2018-12-31 | -16.94% |
| 2018-09-30 | -11.79% |
| 2018-06-30 | -17.86% |
| 2018-03-31 | -41.34% |
| 2017-12-31 | -41.48% |
| 2017-09-30 | -12.42% |
| 2017-06-30 | -10.73% |
| 2017-03-31 | -13.16% |
| 2016-12-31 | -38.58% |
| 2016-09-30 | -8.34% |
| 2016-06-30 | -2.98% |
| 2016-03-31 | -22.36% |
| 2015-03-31 | -34.14% |
